AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01457716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Single inhalation
Study NCT00363168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.3 mg/0.05 ml dose
Study NCT00363168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg/0.05 ml dose
Study NCT01056679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicine
Description: 50mg/m2 day 1 + 15
Study NCT01056679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC
Description: 375mg/m2 day 1 + 15
Study NCT01056679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: day 1 - 21
Study NCT01056679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 6mg/m2 day 1 + 15
Study NCT04790799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment at the skin department at Gentofte Hospital
Description: Treatment in a hospital setting at Gentofte Hospital skin department
Study NCT03851991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbidol
Description: oral
Study NCT01457716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Single inhalation
Study NCT01457716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easyhaler
Description: Inhaler device
Study NCT01457716 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Turbohaler Forte
Description: Inhaler device
Study NCT04263649 — intervention group
Intervention type: DEVICE
Intervention: Peripherally Inserted Central Catheter
Description: insertion of a Peripherally Inserted Central Catheter (PICC)
Study NCT00919230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate tablets
Description: 200mg twice daily for four weeks
Study NCT01503736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ferric citrate
Description: 0g/day ferric citrate capsule, TID for 56 days
Study NCT01503736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: 4g/day ferric citrate capsule, TID for 56 days
Study NCT01503736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: 6 g/day ferric citrate capsule, TID for 56 days
Study NCT02408302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.
Study NCT03411148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly exercise sessions with physical therapist and psychologist
Description: Eight weekly sessions integrating techniques from physical therapy and cognitive behavioral therapy. At the start of each session participants play virtual reality games that target balance and functional gait and then discuss their balance confidence and activity avoidance behaviors with a behavioural counselor. Weekly homework assignments ask participants to report on thoughts causing them to avoid activities and to slowly engage in activities that present increasing levels of fear.
Study NCT03411148 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home-based exercises
Description: Stretching and other exercises are safely taught by physical therapist and then practiced at home following a provided schedule. Participants receive periodic calls to discuss progress.
Study NCT03851991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: controle
Study NCT01422902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasticity-based Cognitive Training
Study NCT01422902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-plasticity-based Training
Description: Computer games
Study NCT04518085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical hypnosis
Description: Single session 20 minutes hypnosis session originally developed and tested by Montgomery et al. (2007) in a similar setting. Delivered by an experienced clinical psychologist.
Study NCT04518085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Acceptance and Commitment Therapy (iACT)
Description: Access to an online platform developed to this study containing video clips and audio files with ACT consistent material
Study NCT04518085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness session
Description: Single session mindfulness session delivered by audio file
Study NCT04518085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as usual as part of post-surical care
Study NCT01056536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured intervention for the prevention of sexually transmitted infections (STI).
Description: The structured intervention will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The intervention will last approximately 5 minutes. At the end of the structured intervention the subjects will be offered free condoms.
Study NCT01056536 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Free condoms
Description: Subjects will be proposed free condoms at the end of the pre-travel consultation.
Study NCT01056536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free condoms
Description: Subjects will be proposed free condoms at the end of the pre-travel consultation.
Study NCT04376671 — intervention group
Intervention type: DEVICE
Intervention: Electroencephalography
Description: The patients underwent EEG recordings according to previously published methods (Bonanni et al., 2008). . EEG recordings were analyzed with methods described in our previous work (Bonanni et al., 2008) by 2 experimenters unaware of the clinical conditions of the subjects. Briefly, quantitative EEGs (QEEGs) were recorded from 21 scalp derivations. Ag/AgCl disk scalp electrodes (19) were placed according to the international 10-20 system, EEG was recorded from Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, Pz, P3, P4, T3, T 4, T5, T6, O1, and O2. Two additional electrodes were placed on A1 and A2. EEG activity was analyzed from single or multiple leads grouped to define the following scalp regions: anterior (Fz, Fp2, F7, Fp1, F3, F4, and F8), central (Cz, C3, and C4), posterior (Pz, P3, P4, O1, and O2), and temporal (T3, T4, T5, and T6).
Study NCT02290418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass
Description: Laparoscopic Gastric Bypass performed with two anastomoses (gastro-enteral and entero- enteral), two limbs (Alimentary limb of length 150cm and Biliary limb of length 75-100cm) and sewing of mesenteric defect.
Study NCT02290418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omega-Loop Gastric Bypass
Description: Laparoscopic Gastric Bypass performed with single anastomosis (gastro-enteral) connecting a long gastric pouch to small bowel with Afferent limb of length 200cm.
Study NCT00937196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo globuli
Description: placebo globuli administered together with verbal suggestions of a hypotensive drug effect
Study NCT00937196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histaminum hydrochloricum globuli
Study NCT05001048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride
Description: Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.
Study NCT05001048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test
Description: Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
Study NCT05001048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isocapnic Acute Hypoxia
Description: During low altitude assessment, participants will be exposed to isocapnic hypoxia equivalent to 3,800m to assess responses to acute exposure.
Study NCT05001048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: During high altitude assessments, participants will breathe an oxygen concentration comparable to their end-tidal values at low altitude for the assessment of the influences of acclimatization.
Study NCT03658772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grapiprant
Description: Cohort 1 will be treated for 1 week with oral grapiprant as a single agent, followed by 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
Study NCT03658772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grapiprant and pembrolizumab
Description: Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
Study NCT01311791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algisyl-LVR
Description: Algisyl-LVR™ device (implants) administered during a surgical procedure
Study NCT01311791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy
Description: as defined per protocol
Study NCT00355719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir (Reyataz)
Description: Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)
Study NCT00355719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (Norvir)
Description: Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)
Study NCT00355719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine (Viramune)
Description: Nevirapine (Viramune): tablets 200 mg (1 tablet/12h\*)
Study NCT06161961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WRL TTP
Description: evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
Study NCT03290326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
Study NCT00843973 — intervention group
Intervention type: PROCEDURE
Intervention: iliac crest bone graft
Description: iliac crest bone graft procedure
Study NCT00843973 — intervention group
Intervention type: PROCEDURE
Intervention: Reamer Irrigator Aspirator
Description: Reamer Irrigator Aspirator (RIA) Procedure
Study NCT00988026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline vs Lymecycline
Description: Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
Study NCT00988026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline vs Lymecycline
Description: Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
Study NCT03542760 — intervention group
Intervention type: DRUG
Intervention: Methylene Blue
Description: Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care
Study NCT02084797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V2R (Vasopressin 2 receptor)
Description: All ten subjects were used as their own controls in this double-blind, randomized controlled trial assessing the effect of the V2R on sweat sodium concentration via use of a V2R blocker (antagonist), stimulator (agonist), against a placebo (drug naive state).
Study NCT03823027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SiPore15™
Description: SiPore15™ is a taste- and odourless white powder, consisting of precisely engineered micrometre sized synthetic amorphous silicon dioxide. The device is made of pure silicon dioxide, SiO2, which has the CAS Number: 112926-00-8 and EC List number: 601-214-2.
Study NCT05969691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validation of IDH1 mutations from the radiomics model
Description: During surgery, clinicians will select several typical target sites for puncture based on the preoperative model outputs. After surgery, the acquired tumour tissues will be subjected to histological diagnosis and pathological diagnosis by professional pathologists, and the results will be compared with the model output to verify its accuracy.
Study NCT03831724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP™ System with FLIP Topography Module
Description: The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.
Study NCT02721888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Study NCT02721888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
Study NCT02721888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT02721888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetic substudy (10 patients)
Study NCT01044498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
Study NCT01044498 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ortho-Novum® 1/35
Description: Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
Study NCT01044498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Novum® 1/35
Description: Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
Study NCT04214015 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study NCT00113139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based coping skills/stress management
Description: Telephone-based coping skills/stress management: 12 weekly sessions.
Study NCT00113139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care participants continued their routine and usual treatments and do not receive the 12 telephone training sessions.
Study NCT02909426 — intervention group
Intervention type: DEVICE
Intervention: Ultrasonography
Description: Radiologists' hand-held bilateral breast ultrasonography for each participant for one time
Study NCT02909426 — intervention group
Intervention type: DEVICE
Intervention: Digital mammography
Description: Full-field digital mammography using one of the equipments from General Electric (GE), Hologic, and Medi-future companies for each participant for one time
Study NCT04251494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid intima media thickness measurement (CIMT)
Description: CIMT is a measurement of the thickness of the two inner layers of the common carotid artery wall. Using ultrasound, a linear array transducer is placed on the surface of the skin at the neck. Electrocardiogram(ECG) electrodes are placed on each wrist and one on the ankle. An image of the common carotid artery (CCA) is then produced in anterior, posterior and lateral views, and saved along with the ECG recording. The wall thickness can then be measured at the same point in the cardiac cycle using semi-automated detection software (Philips QLAB), which can reduce observer variability. The CIMT will be averaged across left and right CIMTs, as the control reference values use an average of both sides.
Study NCT04251494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse Wave Velocity measurement
Description: The PWV measures the speed of a pulse wave travelling between two points in the vascular systems of known distance between them. PWV will be measured by the gold standard carotid-femoral PWV method which is a direct measurement of aortic stiffness. A 3-Lead ECG is connected alongside measurements of the blood velocity trace for the left CCA 2cm proximal to the bifurcation, and for the left common femoral artery origin.
Study NCT04251494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ankle-brachial pressure index (ABPI)
Description: A blood pressure cuff is placed around the ankle and upper arm of the participant. A continuous wave Doppler probe is used over the surface of the skin to locate the artery distal to the cuff (such as the brachial artery in the arm, or the anterior tibial and posterior tibial arteries in the ankle). The cuff is then inflated, and the systolic pressure identified by listening cessation of the sounds produced by the probe corresponding to blood flow in the artery. The ABPI is then the ratio of the highest systolic ankle pressure divided by the highest systolic brachial pressure for the left and right sides of the body.
Study NCT04251494 — intervention group
Intervention type: OTHER
Intervention: Diet questionnaire and diet diary
Description: Dietary information will be collected in two formats. One will be a 14-item questionnaire (Martínez-González et al., 2012), which is a simplified version of a comprehensive food frequency questionnaire. This provides a quick measure of compliance to a Mediterranean dietary pattern and a rough measure of protective and adverse dietary factors that could affect individual CVD risk. The second will be a 3-day diet diary (3DDD). This will consist of participants recording the foods that they consume and the quantities, which will then be analysed for macro- and micronutrient composition once completed.
Study NCT04384458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.
Study NCT04384458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
Study NCT03203668 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 18F-choline PET/CT
Description: 18F-choline PET/CT imaging (neck, mediastinum)
Study NCT03781739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MANP
Description: single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
Study NCT03781739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MANP
Description: single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
Study NCT02534272 — intervention group
Intervention type: OTHER
Intervention: Stool sampling and sequencing of gut microbiota.
Study NCT03198221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clenpiq
Description: bowel preparation
Study NCT03650595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The TRANBERGCLS|Thermal Therapy
Description: MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS\|Thermal Therapy
Study NCT03542448 — intervention group
Intervention type: DEVICE
Intervention: Swept source optical coherence tomography
Description: Measurement of choroidal thickness in myopic patients
Study NCT01457300 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation
Description: Model 1: Regular Assessment of Rehabilitation Goal, Rehabilitation Plan, Weekly Multi-Disciplinary Evaluation and Adjustment of Plan, Regular use of Measurement Scales, Regular Dialog between Personnel, Patient and Relatives. Model 2: More Occasional use of the Listed Activities. Model 1 and Model 2: Physical Training and Functional ADL Training, in Groups, One by One or Self-Training.
Study NCT04724356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Intervention was led once per day, five days a week, over 8 weeks.
Study NCT04724356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Intervention was led once per day, five days a week, over 8 weeks.
Study NCT04432402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide: 10mg、15mg、20mg、25mg qd PO day 1-7, Rituximab: 375 mg/m2 IV day0, Gemcitabine :1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1 (every 14 days as a cycle)
Study NCT03923218 — intervention group
Intervention type: OTHER
Intervention: LL-37 levels in Gingival crevicular fluid
Description: Collected gingival crevicular fluid
Study NCT03923218 — intervention group
Intervention type: OTHER
Intervention: Serum Vitamin D3 levels
Description: Collected serum
Study NCT03923218 — intervention group
Intervention type: OTHER
Intervention: Clinical parameters
Description: Recorded plague index, gingival index, probing depth, clinical attachment level
Study NCT03937323 — intervention group
Intervention type: OTHER
Intervention: Blood lymphocyte subtypes and serum cytokines
Description: Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine the proinflammatory cytokines